With ZEJULA, You Have a Choice About What Comes Next in Your Ovarian Cancer Treatment

ZEJULA is a once-daily oral medicine used for the maintenance treatment of women with recurrent ovarian, fallopian tube, or primary peritoneal cancer when their cancer comes back.

ZEJULA is the first and only once-daily PARP inhibitor used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy.1-3
See below for full Indication.

ZEJULA My Way

As you consider your next steps, learn more about ZEJULA and find out if maintenance treatment is right for you.

Sign up today

ZEJULA offered nearly

4X MORE

time in response to chemotherapy for women with an inherited BRCA mutation vs watch and wait (placebo)1,4

See the data

ZEJULA offered

>2X MORE

time in response to chemotherapy for women without an inherited BRCA mutation vs watch and wait (placebo)1,4

See the data

ZEJULA was evaluated as a maintenance treatment in a double-blind, placebo-controlled phase 3 trial of 553 women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who1*

  • Received at least 2 platinum-based chemotherapy treatments, and
  • Had a complete or partial response to the most recent chemotherapy

The study was designed to measure how long women lived with epithelial ovarian, fallopian tube, or primary peritoneal cancer without their disease getting worse. The treatment benefit of ZEJULA was independently tested in women with the BRCA gene and women without the BRCA gene.1

*65 women who were BRCA-positive received a placebo (eg, sugar pill), and 116 women who were BRCA-negative received a placebo.

Recurrent
Ovarian Cancer

Get more information about what ovarian cancer recurrence might mean for you

Understand Recurrent Ovarian Cancer

Increased Time
in Response

Learn how ZEJULA may extend your time in response

Learn about ZEJULA

Support
During Treatment

Find resources that may help you access and pay for ZEJULA

Get Access and Support
Back to Top